ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Κατάταξη σε μετοχές
#19247
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Τιμή μετοχής
$0.38122017
Τελευταίος συγχρονισμός: 2026-10-16
Κεφαλαιοποίηση
$159.74M
Αλλαγή (1 ημέρα)
2.58%
Αλλαγή (1 έτος)
-71.65%
Χώρα
CN
Εμπόριο ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Κεφαλαιοποίηση: $159.74M
Μέχρι το October 2026, η ImmuneOnco Biopharmaceuticals (Shanghai) Inc. έχει χρηματιστηριακή αξία $159.74M. Αυτό καθιστά τη ImmuneOnco Biopharmaceuticals (Shanghai) Inc. την 19247th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της ImmuneOnco Biopharmaceuticals (Shanghai) Inc. από 2023 έως 2026
1541 σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για 1541 | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$12,534.39
$159.74M
|
$5.252T | +3,287,865.92% | ||
|
$11,935.22
$159.74M
|
$5.001T | +3,130,693.68% | ||
|
$9,966.12
$159.74M
|
$4.176T | +2,614,167.56% | ||
|
$9,469.52
$159.74M
|
$3.968T | +2,483,903.14% | ||
|
$6,770.56
$159.74M
|
$2.837T | +1,775,923.15% |
